Jason Cohen, Editor

About the Author Jason Cohen, Editor


Wedbush Sees 240% Upside for Kala Pharmaceuticals (KALA) Stock; Here’s Why

Wedbush analyst Liana Moussatos is out today with a bullish note on shares of Kala Pharmaceuticals (NASDAQ:KALA), …

This Analyst Thinks Sarepta (SRPT) Stock Can Go to $267

It’s a big day for Sarepta Therapeutics (NASDAQ:SRPT) investors. The company released positive preliminary results from …

A Balanced Take on Valeant (VRX) Following Yesterday’s Sell-Off

Valeant (NYSE:VRX) shares fell 12% yesterday on news that the FDA issued a complete response …

Healthcare Analysts Weigh in on Catalyst Biosciences’ (CBIO) Clinical Hold

Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes …

Sarepta’s (SRPT) Gain Is Wave Life Sciences’ (WVE) Pain

Wave Life Sciences (NASDAQ:WVE) shares tumble nearly 14% in Tuesday’s trading session, following the news that competitor Sarepta …

Oppenheimer Cuts Price Target on Verastem (VSTM) to Reflect Recent Dilution

Verastem (NASDAQ:VSTM) just riled up Wall Street today with enticing Phase Ib/II study results in …

We Still Like Valeant (VRX) Stock Here, Says Healthcare Analyst Louise Chen

Looking for a reason to buy shares of Valeant? How about three reasons, courtesy of Cantor analyst Louise Chen.

Arrowhead Pharmaceuticals (ARWR): Speedy ARO-AAT Enrollment Signals Catalysts to Come, Says Cantor

Arrowhead Research (NASDAQ:ARWR) is a mover and shaker out on the Street today, with investors …

Mizuho Remains Bullish on Valeant (VRX) Shares Following FDA Setback

Valeant (NYSE:VRX) shares are dipping 6% in early trading Monday, after the drug maker announced that …

Top Analyst Shines Light on Global Blood Therapeutic (GBT) Following Phase 2a Results in SCD

Global Blood Therapeutics (NASDAQ:GBT) investors got cold feet today, sending shares tumbling nearly 17%. The …